0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Immune Checkpoint Proteins > OX40 Ligand > Human OX40 Ligand / TNFSF4 Protein, Mouse IgG2a Fc Tag, low endotoxin

Human OX40 Ligand / TNFSF4 Protein, Mouse IgG2a Fc Tag, low endotoxin

  • Synonym
    OX40L,TNFSF4,CD252,Glycoprotein Gp34,TXGP1
  • Source
    Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (OXL-H5250) is expressed from human 293 cells (HEK293). It contains AA Gln 51 - Leu 183 (Accession # P23510-1).
    Predicted N-terminus: Gln 51
  • Molecular Characterization
    Online(Gln 51 - Leu 183) P23510-1

    This protein carries a mouse IgG2a Fc tag at the C-terminus.

    The protein has a calculated MW of 42.3 kDa. The protein migrates as 53-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 0.1 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    No activity loss was observed after storage at:

    1. 4-8°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) SDS-PAGE gel

Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxinHuman OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) ELISA bioactivity

Immobilized Human OX40, Fc Tag (Cat. No. OX0-H5255) at 0.5 μg/mL (100 μL/well) can bind Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) with a linear range of 0.8-13 ng/mL (QC tested).

Bioactivity-FACS
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that recombinant Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) can bind to 293T cell overexpressing human OX40. The concentration of OX40 Ligand is 0.003 μg/ml (Routinely tested).

FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) to 293T overexpressing OX40 was inhibited by increasing concentration of neutralizing anti-OX40 antibody. The concentration of OX40 Ligand used is 0.002 μg/ml. IC50=3.021 μg/ml (Routinely tested).

  • Background
    Tumor necrosis factor ligand superfamily member 4 (TNFSF4) is also known as glycoprotein Gp34, OX40 ligand (OX40L), TAX transcriptionally-activated glycoprotein 1 and CD252, which belongs to the tumor necrosis factor family. TNFSF4 is the ligand for CD134 and is expressed on such cells as DC2s (a subtype of dendritic cells) enabling amplification of Th2 cell differentiation. The interaction of TNFSF4-TNFSF4 is involved in the pathogenesis of multiple autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), carotid artery disease and cancer. Furthermore, similar to other TNF superfamily members, membrane-bound OX40 Ligand (TNFSF4) exists as a homotrimer. Human TNFSF4 shares 46% amino acid sequence identity with its mouse counterpart.
  • References
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $350.00

Price(USD) : $2310.00

Promotion & Exhibitions

  • PEGS Boston 2019
  • PepTalk 2019

Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:3 Details
  • Latest Research Phase:Phase ?

Datasheet & Documentation

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop